Next Article in Journal
Transglutaminase-2 Mediates the Biomechanical Properties of the Colorectal Cancer Tissue Microenvironment that Contribute to Disease Progression
Next Article in Special Issue
Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
Previous Article in Journal
Paralogous HOX13 Genes in Human Cancers
Previous Article in Special Issue
18F-FDG-PET Can Predict Microvessel Density in Head and Neck Squamous Cell Carcinoma
Article

18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study

1
Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy
2
Urology Unit, Academical Medical Centre Hospital, 33100 Udine, Italy
3
Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
4
Department of Urology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
5
Department of Nuclear Medicine, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy
6
Nuclear Medicine Unit, Diagnostic Imaging e Laboratory Medicine Department, University Hospital of Ferrara, 44121 Ferrara, Italy
7
Vita-Salute San Raffaele University, 20132 Milan, Italy
8
Department of Urology, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy
9
Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
10
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
11
Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV—IRCCS, 35128 Padua, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(5), 700; https://doi.org/10.3390/cancers11050700
Received: 11 April 2019 / Revised: 10 May 2019 / Accepted: 16 May 2019 / Published: 20 May 2019
(This article belongs to the Special Issue Role of Medical Imaging in Cancers)
Objectives: To evaluate the ability of 18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40%) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74% (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4%) had recurrence/progression of disease. Moreover, 131 subjects (45.6%) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings. View Full-Text
Keywords: PET/CT; urothelial carcinoma; bladder cancer; upper tract urothelial carcinoma; survival PET/CT; urothelial carcinoma; bladder cancer; upper tract urothelial carcinoma; survival
Show Figures

Figure 1

MDPI and ACS Style

Zattoni, F.; Incerti, E.; Dal Moro, F.; Moschini, M.; Castellucci, P.; Panareo, S.; Picchio, M.; Fallanca, F.; Briganti, A.; Gallina, A.; Fanti, S.; Schiavina, R.; Brunocilla, E.; Rambaldi, I.; Lowe, V.; Karnes, R.J.; Evangelista, L. 18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study. Cancers 2019, 11, 700. https://doi.org/10.3390/cancers11050700

AMA Style

Zattoni F, Incerti E, Dal Moro F, Moschini M, Castellucci P, Panareo S, Picchio M, Fallanca F, Briganti A, Gallina A, Fanti S, Schiavina R, Brunocilla E, Rambaldi I, Lowe V, Karnes RJ, Evangelista L. 18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study. Cancers. 2019; 11(5):700. https://doi.org/10.3390/cancers11050700

Chicago/Turabian Style

Zattoni, Fabio, Elena Incerti, Fabrizio Dal Moro, Marco Moschini, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Andrea Gallina, Stefano Fanti, Riccardo Schiavina, Eugenio Brunocilla, Ilaria Rambaldi, Val Lowe, R. Jeffrey Karnes, and Laura Evangelista. 2019. "18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study" Cancers 11, no. 5: 700. https://doi.org/10.3390/cancers11050700

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop